Cue Biopharma CEO Lin Shao-Lee sells $305,490 in shares
Cue Biopharma CEO Lin Shao-Lee disposed of $305,490 worth of the company’s common stock on October 12, 2026. The sale involved the trading of 11,087 shares across two transactions, each priced between $27.50 and $28.05. According to the company’s disclosure, these sales were not discretionary; they were necessary to meet tax withholding obligations through a sell-to-cover transaction tied to the vesting and settlement of Lin’s restricted stock units.
Lin did not have any control over the timing, price, or quantity of the sold shares. Since the transaction, Cue Biopharma’s stock has dropped, now trading at $18.60, marking a 16.7% decrease over the previous week. Despite this decline, analysts believe the company is undervalued, with CUE featured on InvestingPro’s most undervalued stocks list.
Lin now beneficially owns 694,908 shares of Cue Biopharma common stock directly. Additionally, B.Riley has maintained a positive outlook on Cue Biopharma, assigning a Buy rating and setting a price target of $83.00. This recommendation comes after a key opinion leader event discussing Cue Biopharma’s CUE-221 Phase 2 study on chronic spontaneous urticaria, as well as Cue Biopharma’s recent coverage.
Earlier, Cue Biopharma welcomed CEO Shao-Lee Lin, who previously founded Acelyrin and held significant roles at Horizon and AbbVie. These developments underline Cue Biopharma’s commitment to advancing their drug candidate, CUE-221, for the treatment of allergy-related conditions.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
